What You Should Know:
- CancerIQ, a Chicago-based platform powering early cancer detection and prevention across broad patient populations, announced today it closed a $14M Series B financing round.
- The Series B round was co-led by Merck Global Health Innovation Fund (Merck GHI) and Amgen Ventures with participation from McKesson Ventures, OSF Ventures (the investment arm of OSF HealthCare, a current CancerIQ customer), and HealthX Ventures.
Inequality in
Read More
Oncology Technology Solutions, Services Impacting Patients and Providers
Crisis in the U.S. Healthcare Workforce: Why It’s Time to introduce AI
One of the many acute challenges during the pandemic has been the departure of approximately 18% of the U.S. healthcare workforce,4 resulting in staffing shortages in hospitals. This has impacted the well-being of the remaining healthcare practitioners 5 as well as their patients – many of whom are deferring care that is vital to disease management and overall maintenance of health,6,7 or who do not have access to timely emergency care.1 Though such challenges may be perceived as insurmountable
Read More
Jasper Health Raises $25M for Cancer Care Navigation and Experience Platform
What You Should Know:
- Jasper Health, an NYC-based cancer care coordination and experience platform raise $25M in Series A funding led by General Catalyst.
- The round, which was joined by new and existing investors Human Capital, W Health Ventures, Redesign Health, and 7wireVentures, brings Jasper’s total funding to approximately $31 million.
End-to-End Oncology Solution
1.8 million people are diagnosed with cancer every year. It’s an emotional and complicated process that no one
Read More
Syapse, Pfizer Extends Collaboration to Generate Real-World Evidence in Breast Cancer
What You Should Know:
- Syapse, a real-world evidence company that informs cancer care, announced that it will extend its collaboration with Pfizer to generate real-world evidence in breast cancer.
- This is the third phase of the collaboration, which was first announced in 2019 and renewed in 2021.
Generate Real-World Evidence in Breast Cancer
As part of the next phase of the collaboration, Syapse will provide insights and services to Pfizer, using the Syapse Learning Health Network
Read More
Illumina and Syapse Partner on Biomarker Testing Research Across Oncology Practices
What You Should Know:
- Syapse, a real-world evidence company that informs cancer care, announced a partnership with Illumina aimed at assessing the real-world uptake and actionability of comprehensive genomic profiling in the community oncology health system setting.
- Together, the two companies will work to better understand biomarker testing patterns among clinicians, which have become foundational in identifying treatment options for cancer patients. The insights gleaned from this
Read More
Bayhealth Taps Syapse’s Real-World Data Platform to Optimize Oncology Data
What You Should Know:
- Syapse, a real-world evidence company that informs cancer care, announced a partnership with Bayhealth – central and southern Delaware’s largest healthcare system.
- Bayhealth will leverage Syapse’ multi-source real-world data platform to bring the latest in cancer diagnostics and treatments to Delaware patients, so that they can receive evidence-based care and match to potentially life-saving clinical trial opportunities.
Bringing Data-Driven Approach to
Read More
Cedars-Sinai Cancer Launches ‘Molecular Twin’ Initiative for Precision Cancer Treatment
What You Should Know:
- Cedars-Sinai Cancer and Tempus, a provider of artificial intelligence and precision medicine, are harnessing the power of big data and AI to design personalized cancer treatment options by creating virtual replicas of patients' DNA, RNA, protein and other information to help identify the most effective approach to each individual's disease.
- By creating these "molecular twins," scientists can genetically classify cancer genes and proteins of particular tumors
Read More
Ontada, Merck Partner to Facilitate Real World Evidence Studies for Cancer Care
What You Should Know:
- Ontada, McKesson’s oncology and insights business, announced a strategic agreement with Merck, known as MSD outside the United States and Canada, that will facilitate the development of real-world research excellence and innovation. This agreement enables the two healthcare leaders to harness the power of real-world evidence (RWE) towards the common goal of improving patient outcomes and the quality of cancer care.
- Ontada and Merck’s combined experience and
Read More
U of Chicago Med & COTA to Address Racial Disparities in Cancer Using RWD
What You Should Know:
- COTA, Inc., an oncology real-world data and analytics company and the University of Chicago Medicine announced a research collaboration agreement to investigate racial disparities of care in multiple myeloma to better understand differences in the diagnosis, treatment patterns, and outcomes of patients with this type of cancer.
- Multiple myeloma is the second-most-common hematologic malignancy, with an estimated 34,920 new cases and 12,410 deaths expected to occur
Read More
PAVmed Launches Veris Health With Acquisition of Oncodisc –M&A
What You Should Know:
- PAVmed announced today their launch of digital health company, Veris Health, along with Veris' acquisition of Oncodisc.
- Oncodisc was created by James Mitchell, M.D. and Andrew Thoreson, M.D. and brings the first implantable vascular access port with biologic sensors and wireless communication, combined with an oncologist-designed remote digital healthcare platform to improve outcomes and optimize the delivery of cost-effective care
Read More
